SAN FRANCISCO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- On July 24, 2025, the European Medicines Agency (“EMA”) recommended the refusal of the marketing authorization for ELEVIDYS, Sarepta’s medication intended for the treatment of Duchenne muscular dystrophy. This news prompted another significant decline in the price of Sarepta (NASDAQ: SRPT) shares.

The EMA’s recommendation follows a slew of bad news for Sarepta investors, including patient deaths that resulted in sharp stock price declines, a securities class action (styled Dolgicer v. Sarepta Therapeutics, Inc., et al. , No. 1:25-cv-05317 (S.D.N.Y.)), a major company restructuring that involves, in part, a 36% workforce reduction (500 employees) and other steps to annually save about $400 million, and the company’ agreement with the FDA t

See Full Page